

Regularly Scheduled Series

You are invited to the OUHSC Department of Pediatrics Grand Rounds

Course No. 22D06

Wednesday, February 9, 2022

12:15 – 1:15pm

To Record Your Attendance: Text 10447 to 405-562-5828 during Grand Rounds

You will still need to text in your attendance to receive CME and access the survey.

Participants can text in 15 minutes before the scheduled start, all during, and 45 minutes after the scheduled end.

*** * *VIRTUAL* * ***

Join Zoom Meeting

<https://zoom.us/j/93633681340>

Meeting ID: 936 3368 1340

Password: 00001111

One tap mobile: US: [+1669219259993633681340#...*00001111#](tel:+1669219259993633681340#...*00001111#) or
[+1669900683393633681340#...*00001111#](tel:+1669900683393633681340#...*00001111#)

NOTE : The meeting host will admit you to the meeting a few minutes before 12:15.
If you login early, please wait to be admitted.

Attending a Zoom meeting:

If you have not yet attended a Zoom meeting then please visit this site (below) for information you will need:

<https://support.zoom.us/hc/en-us/articles/201362193-Joining-a-Meeting>

Title:

“Adventures in Pediatric Genomic Medicine: Hits and Misses, Ethics and Equity”

Presented by:

Wayne W. Grody, M.D., Ph.D.

Professor

Divisions of Medical Genetics
and Molecular Diagnostics

Departments of Path. & Lab. Medicine,
Pediatrics, and Human Genetics

UCLA School of Medicine

UCLA Institute for Society and Genetics

Director, Molecular Diagnostic Laboratories
and Clinical Genomics Center

UCLA Medical Center

CHF Mulvihill Altshuler Lecture

Invited by: Pediatric Genetics

OUHSC Department of Pediatrics

Professional Practice Gap:

- 1) Many physicians currently in practice received little exposure to concepts of human and molecular genetics in their training years, and even much of that has now been superseded by revolutionary modern discoveries and technologies.
- 2) The advent of “personalized” or “genomic” medicine has been promulgated and sometimes hyped by the federal government, the pharmaceutical industry, direct-to-consumer genetic testing companies and the lay press, and patients are now coming into the clinic with many preconceived notions about it. Clinicians must be prepared to address their questions confidently and realistically.
- 3) The genomics of race has evolved rapidly and, like the societal implications, has become something of a moving target. Clinicians need to gain some basic understanding of this highly fraught area, since it directly impacts genomic sequencing access, interpretation, and equity.

Learning Objectives: Upon completion of this session, participants will improve their competence and performance by being able to:

- 1) Appraise the power and pitfalls of current clinical genomic testing as compared to traditional single-gene genetic testing.
- 2) Apply the clinical utility, diagnostic yield and interpretive challenges of this technology, based on our ten years’ experience delivering this service to undiagnosed patients at UCLA.
- 3) Evaluate the unique ethical questions raised by this testing, including the disclosure of potentially life-threatening “incidental findings” and issues of access and equity of various populations as currently defined.

If you wish to view video tapes of past GR, go to <https://mediasite.ouhsc.edu/Mediasite/Channel/ch-pedsgr>

Note: We do not have permission from all presenters to videotape their presentations.

A list of upcoming Pediatric GR topics can be found at: <https://medicine.ouhsc.edu/Academic-Departments/Pediatrics/Research-Education/Grand-Rounds>

Accreditation Statement: The University of Oklahoma College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Oklahoma College of Medicine designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Mitigation Statement: The University of Oklahoma College of Medicine, Office of Continuing Professional Development has reviewed this activity’s speaker and planner disclosures and has mitigated all relevant financial relationships with ineligible companies, if applicable.

Equal Opportunity Statement: The University of Oklahoma, in compliance with all applicable federal and state laws and regulations, does not discriminate on the basis of race, color, national origin, sex, sexual orientation, genetic information, gender identity, gender expression, age, religion, disability, political beliefs, or status as a veteran in any of its policies, practices, or procedures. This includes, but is not limited to: admissions, employment, financial aid, housing, services in educational programs or activities, or health care services that the university operates or provides.

To file a grievance related to the non-discrimination policy, report sexual misconduct, and/or file a formal complaint of sexual misconduct, please utilize the reporting form at link ou.edu/reportingform.

Inquiries regarding non-discrimination policies may be directed to the Office(s) of Institutional Equity as may be applicable – Norman campus: (405) 325-3546/3549, Health Sciences Center: (405) 271-2110, or OU-Tulsa Title IX Office: (918) 660-3107. Additionally, individuals may visit www.ou.edu/eoo.

Accommodation Statement: For accommodations, please contact Cindy Dibler at Cindy-Dibler@ouhsc.edu.

Disclaimer Statement: Statements, opinions and results of studies contained in the program are those of the presenters and authors and do not reflect the policy or position of the Board of Regents of the University of Oklahoma (“OU”) nor does OU provide any warranty as to their accuracy or reliability.

Every reasonable effort has been made to faithfully reproduce the presentations and material as submitted. However, no responsibility is assumed by OU for any claims, injury and/or damage to persons or property from any cause, including negligence or otherwise, or from any use or operation of any methods, products, instruments or ideas contained in the material herein.

Policy on Planner and Presenter Disclosure: It is the policy of the University of Oklahoma College of Medicine that the faculty and presenters identify all financial relationships with ineligible companies relating to the topics of this educational activity, and also discloses discussions of off-label or investigational drugs/devices and/or therapies during their presentation(s).

Acknowledgement of Commercial and In-Kind Support: **Commercial support** is financial, or in-kind, contributions given by an ineligible company, which is used to pay all or part of the costs of a CME activity. An ineligible company is any company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

This activity received no commercial or in-kind support.

Disclosure & Mitigation Report

The University of Oklahoma College of Medicine and the Irwin H. Brown Office of Continuing Professional Development must ensure balance, independence, objectivity and scientific rigor in all its accredited CE activities. We have implemented a process where everyone who is in a position to control the content of an educational activity has identified to us all financial relationships with ineligible companies. In addition, should it be determined that a relevant financial relationship exists, this must be mitigated prior to the activity. This policy is designed to provide the target audience with an opportunity to review any affiliations between the CE planners and presenters and ineligible companies for the purpose of determining the potential presence of bias or influence over educational content. The following is a summary of this activity’s disclosure and mitigation information.

Role	First Name	Last Name	Nature of Relevant Financial Relationship		
			Ineligible Companies	What was received?	For what role?
Planning Member/ Moderator	H. Christine	Allen, MD	I have no financial relationships or affiliations with ineligible companies to disclose.		
Planning Member/ Moderator	Muhammad A.	Altaf, MD	I have no financial relationships or affiliations with ineligible companies to disclose.		
Planning Member/ Moderator/Presenter	Ami B.	Bax, MD	I have no financial relationships or affiliations with ineligible companies to disclose.		
Planning Member/ Moderator	Sanjay I.	Bidichandani, MBBS, PhD	I have no financial relationships or affiliations with ineligible companies to disclose.		
Planning Member/ Moderator	Amanda L.	Bogie, MD	I have no financial relationships or affiliations with ineligible companies to disclose.		
Co-Course Director/ Moderator	Stephanie D.	DeLeon, MD	I have no financial relationships or affiliations with ineligible companies to disclose.		
Course Contact	Cindy G.	Dibler	I have no financial relationships or affiliations with ineligible companies to disclose.		
Planning Member/ Moderator	Morris R.	Gessouroun, MD	I have no financial relationships or affiliations with ineligible companies to disclose.		
Presenter	Wayne W.	Grody, MD, PhD	I have no financial relationships or affiliations with ineligible companies to disclose.		
Course Director/ Moderator	Casey N.	Hester, MD	I have no financial relationships or affiliations with ineligible companies to disclose.		

Role	First Name	Last Name	Nature of Relevant Financial Relationship		
			Ineligible Companies	What was received?	For what role?
Planning Member/ Moderator	Janna M.	Journeycake, MD, MSCS	I have no financial relationships or affiliations with ineligible companies to disclose.		
Planning Member/ Moderator	Amy B.	Middleman, MD, MSEd, MPH	Up to Date	Royalties	Section Editor/Author
			Pfizer	Research fund to OUHSC	PI
Planner/Moderator: The conflict was resolved by Dr. Middleman agreeing to recuse herself from planning content in the conflicted area and limiting her role to the introduction of presenters, fielding questions and moderating the flow of discussion between participants and presenters.					
Planning Member/ Moderator	Edward D.	Overholt, MD	I have no financial relationships or affiliations with ineligible companies to disclose.		
Planning Committee / Moderator	Ana I.	Ana I. Quintero-Del Rio, MD, MPH, FAAP	I have no financial relationships or affiliations with ineligible companies to disclose.		
Planning Member/ Moderator	Jane F.	Silovsky, PhD	I have no financial relationships or affiliations with ineligible companies to disclose.		
Planning Member/ Moderator	David P.	Sparling, PhD	I have no financial relationships or affiliations with ineligible companies to disclose.		
Planning Member/ Moderator	Trent E.	Tipple, MD	I have no financial relationships or affiliations with ineligible companies to disclose.		
Planning Member/ Moderator	Donna L.	Tyungu, MD	I have no financial relationships or affiliations with ineligible companies to disclose.		
Planning Member/ Moderator	Ikuyo	Yamaguchi, MD, PhD	I have no financial relationships or affiliations with ineligible companies to disclose.		